DEAL for Family Accommodation

Phase-Based Progress Estimates
Family Accommodation+5 More
DEAL - Behavioral
Any Age
All Sexes
What conditions do you have?

Study Summary

This trial will test a new intervention, DEAL, to help parents of children with autism who demonstrate severe problem behavior. The intervention is based on Acceptance and Commitment Therapy and Behavioral Activation strategies.

Eligible Conditions
  • Family Accommodation
  • Behavioural Problem
  • Nonadherence

Treatment Effectiveness

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: Change from Time 1 (Week 1) to Time 2 (Week 7)

Week 7
Accommodation to Adherence Change Score
Cognitive Fusion
Experiential Avoidance
Parenting Stress

Trial Safety

Trial Design

2 Treatment Groups

Treatment as Usual
1 of 2
Treatment + DEAL
1 of 2

Active Control

Experimental Treatment

50 Total Participants · 2 Treatment Groups

Primary Treatment: DEAL · No Placebo Group · N/A

Treatment + DEAL
Experimental Group · 1 Intervention: DEAL · Intervention Types: Behavioral
Treatment as UsualNoIntervention Group · 1 Intervention: Treatment as Usual · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: change from time 1 (week 1) to time 2 (week 7)

Who is running the clinical trial?

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.Lead Sponsor
81 Previous Clinical Trials
24,389 Total Patients Enrolled
Organization for Autism ResearchOTHER
5 Previous Clinical Trials
89 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have not yet reached the age of 18 years.\n\nThe study is expected to take 12 months.
The child is diagnosed with ASD, as confirmed by the Gilliam Autism Rating Scale-3.
Child problem behavior is socially-maintained as identified via functional analysis.
You must be fluent in English.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.